<DOC>
	<DOCNO>NCT02566551</DOCNO>
	<brief_summary>The purpose prospective randomize control study compare improvement symptom benign prostatic hyperplasia ( BPH ) improvement QoL , patient undergo prostatic artery embolization ( PAE ) conventional transurethral resection prostate ( TURP ) .</brief_summary>
	<brief_title>Prospective Controlled Randomized Study PAE v TURP BPH Treatment .</brief_title>
	<detailed_description>The purpose prospective randomize control study compare improvement symptom benign prostatic hyperplasia ( BPH ) assess International Prostate Symptom Score ( IPSS ) improvement QoL assess QoL questionnaire patient undergoing prostatic artery embolization ( PAE ) patient similar characteristic undergoing conventional transurethral resection prostate ( TURP ) .</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<criteria>Patients evaluate Urology Service BPH , candidate TURP . Signed informed consent Lower urinary tract symptom ( LUTS ) secondary BPH least 6 month prior study AND/OR baseline IPSS Score &gt; 13 AND/OR acute urinary retention impossibility remove urinary catheter AND/OR BPH symptom refractory medical treatment medication contraindicate , tolerate refused Prostate size least 50 gram measure MRI Patient must meet ONE follow criterion : 1 . Baseline Prostate Specific Antigen ( PSA ) &lt; 4 ng/mL ( prostate biopsy require ) 2 . Baseline PSA &gt; 4 ng/mL ≤10 ng/mL AND free PSA &gt; 15 % total PSA ( prostate biopsy require ) 3 . Baseline PSA &gt; 4 ng/mL ≤10 ng/mL AND free PSA &lt; 15 % total PSA AND negative prostate biopsy result ( minimum 12 core biopsy ) 4 . Baseline PSA &gt; 10 ng/mL AND negative prostate biopsy ( minimum 12 core biopsy ) Active urinary tract infection Patients cystoscopy finding suspicious bladder cancer must undergo biopsy negative histopathology report enrol study Biopsy proven prostate bladder cancer The following patient must undergo prostate biopsy minimum 12 core negative histopathology report enrol study : Patients digital rectal examination ( DRE ) find suspicious prostate cancer Patients baseline PSA level &gt; 10 ng/mL Patients baseline PSA level &gt; 4 ng/mL &lt; 10 ng/mL AND free PSA &lt; 15 % total PSA Bladder atonia , neurogenic bladder disorder neurological disorder impact bladder function ( eg multiple sclerosis , Parkinson 's disease , spinal cord injury , etc ) Urethral stricture , bladder neck contracture , sphincter abnormality , urinary obstruction due cause BPH , potentially confound bladder urethral disease condition Allergy iodinate contrast agent Hypersensitivity gelatin product Previous nonmedical BPH treatment , include surgery , TURP , needle ablation , microwave laser therapy , balloon dilation , stent implantation , invasive treatment prostate Known major iliac arterial occlusive disease know condition catheterization prostatic artery contraindication embolization , vasospasm , anatomical variation imply risk embolization , bleeding , prostatic artery diameter inferior microcatheter profile , pelvic inflammatory disease Contraindication magnetic resonance image History prostatitis last 5 year , totally controlled medical treatment History pelvic irradiation radical pelvic surgery Coagulation disturbances normalized medical treatment</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Prostatic artery embolization</keyword>
	<keyword>Transurethral resection prostate</keyword>
</DOC>